The purpose of the trial is to see whether regular treatment with Tezepelumab can reduce the number of bronchial exacerbations over a year compared with usual care. After a screening visit, eligible individuals will begin a series of sub‑cutaneous injections (given under the skin) of the study drug for 12 months, with regular clinic visits to monitor health, record any worsening of symptoms, and adjust other medicines such as corticosteroids (anti‑inflammatory drugs). The study will not involve any changes to standard medical care other than the study medication.

During the year, participants will undergo simple breathing tests, including spirometry (a test that measures how fast and how much air can be exhaled) and plethysmography (a test that measures total lung volume). Blood and sputum samples will be taken to check levels of eosinophils (a type of white blood cell) and IgE antibodies, which are linked to allergic inflammation. Questionnaires about breathlessness, cough, and overall quality of life will also be completed to help evaluate any improvement in daily functioning.

The purpose of this research is to determine whether giving both an RSV vaccine to pregnant mothers and nirsevimab to their babies at 4 months of age works better than giving only nirsevimab to infants during RSV season. The study will track how well these approaches protect babies from developing RSV-related breathing problems during their first year of life.

Participants will be divided into two groups. In one group, pregnant mothers will receive the Abrysvo vaccine between weeks 32 and 36 of pregnancy, and their babies will later receive Beyfortus at 4 months of age. In the other group, babies will receive only Beyfortus during the RSV season. The babies’ health will be monitored throughout their first year of life to check for any breathing problems or infections.

The purpose of the study is to determine if these corticosteroids can effectively reduce the risk of recurrent wheezing and asthma in young children. Participants in the study will receive either the dexamethasone treatment or a placebo. The study will monitor the children over a period of time to see how many experience new episodes of wheezing or develop asthma, which is a condition that causes the airways to become inflamed and narrow, making it difficult to breathe.

Throughout the study, researchers will also observe other factors such as the duration and severity of any breathing difficulties, the children’s overall quality of life, and their growth in terms of height and weight. This information will help determine the effectiveness of the treatment in preventing asthma and improving the health outcomes for children who have had a severe wheezing episode due to rhinovirus.

Participants in the study will be children aged 6 weeks to 12 years who are hospitalized and require additional oxygen. The study will compare two different oxygen level targets to see which one is more effective in helping children recover faster. The trial will monitor various aspects of the children’s recovery, including the time it takes for them to meet all discharge criteria, the length of their hospital stay, and their overall health after leaving the hospital.

Throughout the study, researchers will also look at other factors such as the number of admissions to the pediatric intensive care unit (PICU), the time spent on oxygen therapy, and the duration of symptoms. Additionally, the study will consider the children’s quality of life, parental anxiety, and the economic impact of the treatment. The goal is to find a safe and effective way to manage oxygen levels in children with respiratory distress, ultimately improving their recovery and overall health.